Discover sponsored genetic testing programs

No-Charge Genetic Testing and Counseling Program for Sensorineural Hearing Loss

In partnership with Eli Lilly and Company, the Resonate^® program in the U.S. offers no-charge genetic testing and counseling for sensorineural hearing loss. No-charge genetic testing is also available in Brazil and Mexico. Resonate uses a comprehensive panel of nearly 300 genes to potentially determine whether there is an underlying genetic cause of hearing loss.

Alnylam Act^® Acute Hepatic Porphyrias

In partnership with Alnylam, this program offers no-charge genetic testing and counseling for patients with a family history or suspected diagnosis of acute hepatic porphyria.

Alnylam Act^® hATTR Amyloidosis

Sponsored by Alnylam, this program offers no-charge genetic testing and counseling for patients with a family history or suspected diagnosis of hereditary ATTR (hATTR) amyloidosis.

Alnylam Act^® Primary Hyperoxaluria Type 1 (3 genes)

Alnylam offers a no-charge genetic testing and counseling program for patients with a family history or suspected diagnosis of primary hyperoxaluria type 1.

Alnylam Act^® Primary Hyperoxaluria Type 1 (45 genes)

Alnylam offers a no-charge genetic testing and counseling program for patients with a family history or suspected diagnosis of primary hyperoxaluria type 1.

NavigATTR Sponsored Testing Program

In partnership with AstraZeneca, this program provides sponsored genetic testing to eligible patients to detect TTR gene variants that may lead to hereditary transthyretin amyloidosis (hATTR), a protein misfolding disorder in which deposition of TTR amyloid aggregates causes multisystem organ dysfunction.

CardioNavigATTR (36 genes)

In partnership with AstraZeneca, this program provides no-cost genetic testing to detect TTR gene variants that may lead to hereditary transthyretin amyloidosis (hATTR), a protein misfolding disorder in which deposition of TTR amyloid aggregates causes multisystem organ dysfunction. Proper identification of an underlying pathogenic TTR gene variant is critically important for patients, their offspring, and siblings. No-cost TTR gene testing is available to patients in the U.S. with a clinical diagnosis of ATTR amyloidosis or a family history of hATTR. TTR gene testing for patients meeting eligibility criteria must be ordered by a qualified health care provider.

NeuroNavigATTR (66 genes)

In partnership with AstraZeneca, this program provides no-cost genetic testing to detect TTR gene variants that may lead to hereditary transthyretin amyloidosis (hATTR), a protein misfolding disorder in which deposition of TTR amyloid aggregates causes multisystem organ dysfunction. Proper identification of an underlying pathogenic TTR gene variant is critically important for patients, their offspring, and siblings. No-cost TTR gene testing is available to patients in the U.S. with a clinical diagnosis of ATTR amyloidosis or a family history of hATTR. TTR gene testing for patients meeting eligibility criteria must be ordered by a qualified health care provider.

No-Cost Genetic Testing Program for Friedreich Ataxia (FA)

Sponsored by Biogen, this program provides no-cost genetic testing for Friedreich ataxia(FA), a neurodegenerative disease characterized by progressive ataxia (ataxic gait and limbs), dysarthria, dysphagia, decreased proprioception, distal muscle weakness, peripheral sensory neuropathy, absent lower limb tendon reflexes, spasticity, scoliosis, pes cavus, and hypertrophic cardiomyopathy. No-cost FA testing is available for patients 16 years of age or older, suspected of or have a clinical diagnosis of FA, and be a resident of the United States or Puerto Rico. The test must be ordered by a qualified healthcare provider.

DetectHypopara^™ Sponsored Testing Program

In partnership with Calcilytix Therapeutics, this program provides physicians with access to no-cost genetic testing for patients, who have a clinical diagnosis of non-surgical hypoparathyroidism or hypocalcemia suspected to be of genetic cause, or meet other eligibility criteria for testing. This program is available for patients and providers in the US & Canada.

My Retina Tracker Program

The My Retina Tracker Genetic Testing Program offers individuals with a clinical diagnosis of an Inherited Retinal Disease (IRD) access to high-quality diagnostic testing, genetic counseling, and connection to a growing IRD registry at no cost to the patient. The Foundation Fighting Blindness, a nonprofit organization dedicated to finding treatments for IRD, and Spark Therapeutics sponsor the Program.

No-Cost Genetic Testing Program for Rare Calcification Disorders ENPP1 and ABCC6 Deficiencies

This program sponsored by Inozyme Pharma offers global, no-cost genetic testing for the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP binding cassette subfamily C member 6 (ABCC6) genes. These genes are implicated in two rare, severe, debilitating calcification disorders: ENPP1 Deficiency and ABCC6 Deficiency. Both these disorders can manifest as generalized arterial calcification of infancy (GACI) type 1 in infancy and then autosomal recessive hypophosphatemic rickets type 2 (ARHR2) in the case of ENPP1 Deficiency or Pseudoxanthoma elasticum (PXE) in the case of ABCC6 Deficiency post infancy.

Testing for one or two variants (post-natal)

Targeted prenatal testing for known familial variants

ABCC6 Deficiency Only

This program sponsored by Inozyme Pharma offers global, no-cost genetic testing for the ABCC6 gene associated with Pseudoxanthoma Elasticum (PXE). This no charge testing is being offered to patients who meet testing eligibility criteria and must be ordered by a qualified healthcare provider.

Genetic Testing Program for Amyotrophic Lateral Sclerosis (ALS)

In partnership with Ionis Pharmaceuticals, this program provides genetic testing for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron impairment in the cortex, brain stem, and spinal cord. ALS testing is available for patients with a clinical diagnosis or family history of ALS and is being offered to residents of the U.S. and Canada who meet testing eligibility criteria. The test must be ordered by a qualified healthcare provider.

Genetic Testing Program for Familial Chylomicronemia Syndrome (FCS)

In partnership with Ionis Pharmaceuticals, this program provides genetic testing for familial chylomicronemia syndrome (FCS), a genetic condition which is characterized by high plasma triglyceride levels resulting from improper breakdown of chylomicron lipoproteins by the LPL enzyme. FCS testing is available for patients with a clinical diagnosis of FCS and is being offered to residents of the US and Canada who meet testing eligibility criteria. The test must be ordered by a qualified healthcare professional.

Decode DEB Sponsored Testing Program

In partnership with Krystal Biotech, Inc., this program offers no-charge genetic testing for patients with suspected dystrophic epidermolysis bullosa (DEB) and qualifying family members of patients diagnosed with DEB. This program is available to patients in the United States, including Puerto Rico.

Movement Disorder Genetic Test Program

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify the genetic cause of movement disorders through a 938-gene next generation sequencing panel. This program is available to residents in North America (US and Canada) who meet eligibility criteria and must be ordered by a qualified healthcare provider.

No-Cost Patient Genetic Testing Program for Cholestasis

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify the genetic cause of cholestasis through a 77-gene panel. This program is available to US resident who meet eligibility criteria and must be ordered by a qualified healthcare provider.

Behind the Blur: No-Cost Patient Genetic Testing Program for Early-Onset Bilateral Cataracts

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify the genetic cause of early onset, often bilateral, cataracts through a 66-gene panel. This program is available for patients in the US who meet eligibility criteria and must be ordered by a qualified healthcare provider.

No-Cost Patient Testing Program for Peroxisome Biogenesis Disorder - Zellweger Spectrum Disorder (PBD-ZSD)

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD) through a 13-gene panel. This program is available for patients in the US who meet eligibility criteria and must be ordered by a qualified healthcare provider.

No-Cost Genetic Testing Program for States Initiating Newborn Screening for X-linked Adrenoleukodystrophy (X-ALD)

Mirum Pharmaceuticals has partnered with PreventionGenetics to offer a no-cost genetic testing program to help identify peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD) and other disorders within the states offering X-ALD newborn screening programs. Testing will be offered to children who screened positive for X-ALD on initial state newborn screen but negative for the disease after further evaluation.

Amplify^™ Sponsored Testing Program

In partnership with Regeneron Pharmaceuticals, Amplify^™ is a no-charge genetic testing program for children diagnosed with auditory neuropathy. Amplify^™ strives to remove barriers to genetic diagnosis for patients born with auditory neuropathy.

No-charge Sponsored Testing Program for Rare Genetic Diseases of Obesity

This program is sponsored by Rhythm Pharmaceuticals and is intended to expand access to genetic testing for individuals with a rare genetic disease of obesity. The test sequences 87 genes associated with rare genetic diseases of obesity. Tests may only be ordered by licensed US or Canadian healthcare providers and patients must reside in the United States, its territories, or Canada.

POMC/PCSK1/LEPR Companion Diagnostic (CDx) Panel

This test is a companion diagnostic device intended to select adult and pediatric patients 6 years of age and older who have obesity and certain variants in POMC, PCSK1, or LEPR genes for treatment with IMCIVREE^® (setmelanotide) in accordance with the approved therapeutic product labeling.

No-Cost Genetic Testing Program for Thymidine Kinase 2 Deficiency (TK2 Gene)

In partnership with UCB, this No-Cost Genetic Testing Program is available to individuals with a suspected or clinical diagnosis of Thymidine Kinase 2 Deficiency (TK2d) is a rare, inherited, and debilitating myopathic mitochondrial disease that is often fatal and can present at any age. It is a mitochondrial DNA depletion disorder.

No-Cost Genetic Testing Program for Thymidine Kinase 2 Deficiency (55 genes)

In partnership with UCB, this No-Cost Genetic Testing Program is available to individuals with a suspected or clinical diagnosis of Thymidine Kinase 2 Deficiency (TK2d) is a rare, inherited, and debilitating myopathic mitochondrial disease that is often fatal and can present at any age. It is a mitochondrial DNA depletion disorder.

Xeris Pharmaceuticals Uncovering Periodic Paralysis

The Uncovering Periodic Paralysis Program is a sponsored genetic testing program for individuals living in the U.S. and U.S. territories, who experience episodic muscle weakness or temporary paralysis triggered by common factors associated with primary hyperkalemic or hypokalemic periodic paralysis. Xeris Pharmaceuticals^® and its associated logo are trademarks of Xeris Pharmaceuticals, Inc. Used by permission.